Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derun Li

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
ACS Medicinal Chemistry Letters|September 17, 2021
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 InhibitorsBrett Hopkins, Hongjun Zhang, Indu Bharathan, et al.
ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.
ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer ImmunotherapyMatthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.
ACS Medicinal Chemistry Letters|June 20, 2014
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor AgonistsDerun Li, Zhicai Wu, Yang Yu, et al.
Journal of Medicinal Chemistry|April 29, 2026
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent BindersJustin A Caravella, Angela V Toms, Nikolay Sitnikov, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2021
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitorsWensheng Yu, Yongqi Deng, Brett Hopkins, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 DiabetesLiangqin Guo, Dann L Parker, Yi Zang, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|September 17, 2021
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 InhibitorsBrett Hopkins, Hongjun Zhang, Indu Bharathan, et al.
ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.
ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer ImmunotherapyMatthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.
ACS Medicinal Chemistry Letters|June 20, 2014
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor AgonistsDerun Li, Zhicai Wu, Yang Yu, et al.
Journal of Medicinal Chemistry|April 29, 2026
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent BindersJustin A Caravella, Angela V Toms, Nikolay Sitnikov, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2021
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitorsWensheng Yu, Yongqi Deng, Brett Hopkins, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 DiabetesLiangqin Guo, Dann L Parker, Yi Zang, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Pageof 5